jeudi 5 septembre 2019

Onco Actu du 5 septembre 2019


1. BIOLOGIE



MD Anderson study confirms protein as potential cause of most common type of pancreatic cancer [MD Anderson Cancer Center]











1.4 BIOLOGIE - TECHNOS, MODÈLES



Deep-learning AI technique helps scientists see more clearly inside the cell [STAT]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Another Patient Has Died From Lung Disease After Vaping [NY Times]











Michigan becomes first state to ban flavored e-cigarettes [The Hill]











3.2 PRÉVENTION - OBÉSITÉ



Taxing confectionery, biscuits, and cakes to control obesity [BMJ]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



FAK Protein Linked to Chemotherapy Resistance in Ovarian Cancer [UCSD]











NIH, Cincinnati Children’s scientists develop potential strategy against leukemia drug resistance [NIH]











5.10 TRAITEMENTS - ESSAIS



Enough with the me-too drugs. New treatments should be worthy of the people who invest their lives in clinical trials [STAT]










5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Nkarta nets $114M to push natural killer cell therapies into the clinic [Fierce Biotech]











The world’s first T-cell therapy for a solid tumor cancer is made in Philly [Philadelphia Inquirer]











5.12.6 IMMUNOTHÉRAPIES - AMM



European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC) [Merck]










5.17 TRAITEMENTS - RADIOTHÉRAPIE



New guideline clarifies role of radiation therapy in pancreatic cancer treatment [ASTRO]











5.2 PHARMA



Cancer drugs' share of new FDA approvals doubled this decade thanks to smarter R&D: report [Fierce Pharma]










Pfizer’s chessmaster: How a top scientist helped invigorate a lumbering drug giant [STAT]











5.2.1 PHARMA - PARTENARIATS



AstraZeneca to adopt Schrödinger's molecule-modeling platform for drug discovery [Fierce Biotech]











5.2.3 PHARMA - ÉCONOMIE



Versant's Repare raises $82M to trial synthetic lethality drugs [Fierce Biotech]











Versant-backed precision oncology startup Repare Therapeutics scores $82M+ in latest round [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Ex-FDA chiefs, non-profits take Ned Sharpless' corner as clock ticks down on Trump's pick [EndPoints]











5.9 AACR



Upcoming AACR Meeting Focuses on Recent Advances in Pancreatic Cancer Research [Cancer Research Catalyst]











6. LUTTE CONTRE LES CANCERS



Dana-Farber and the Broad Institute launch new patient partnered research initiative [Dana-Farber Cancer Institute]











NCI Annual Plan & Budget Proposal for Fiscal Year 2021 [NCI]










6.6 PUBLICATIONS



World Health Organization Backs Open-Access Plan S [The Scientist]











6.7.1 IA/BIOINFORMATIQUE



Has AI Discovered a Drug Now? Guess. [In The Pipeline]











Welcoming Medicine To The Machine [Health Affairs]